[Management of side effects of targeted therapies in renal cancer: cutaneous side effects].
Targeted therapies used (angiogenesis inhibitors and mTOR inhibitors) in advanced renal cell carcinoma have a constellation of reaction affecting the skin, hair and nails. This guideline describes the incidence, clinical presentation and treatment of dermatologic side effects that develop with the use of targeted therapies (sunitinib, sorafenib, pazopanib, bevacizumab, everolimus, temsirolimus).